Drug Type Synthetic peptide |
Synonyms BC-201, VAL 201, VAL-301 + [1] |
Target |
Mechanism SRC inhibitors(Tyrosine-protein kinase SRC inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC55H87N19O11 |
InChIKeyOCAUTAUXGFCFEB-MGFBIKGDSA-N |
CAS Registry957791-38-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 2 | - | 01 Oct 2014 | |
Metastatic Prostate Carcinoma | Phase 2 | - | 01 Oct 2014 | |
Prostatic Cancer | Phase 2 | - | - | |
Breast Cancer | Preclinical | FI | 15 Apr 2013 | |
Sepsis | Preclinical | - | - |
Phase 1/2 | 12 | (Cohort 1: 0.5 mg/kg) | qtdtkwnotl(wpaejstcvm) = wkndenavoi aiyimnfkqe (acitnpydvh, ddhfyzzvin - vygwjenhdm) View more | - | 08 Nov 2021 | ||
(Cohort 5: up to 8 mg/kg) | qtdtkwnotl(wpaejstcvm) = qfknmmnrtb aiyimnfkqe (acitnpydvh, unbxsmjpbe - tbsfuiuaek) View more |